Lorbrena (lorlatinib) — Medica
Pediatric Central Nervous System Cancer – ALK-positive diffuse high-grade glioma
Initial criteria
- Patient is age < 18 years
- Tumor is positive for anaplastic lymphoma kinase (ALK)
- Medication is used as adjuvant therapy OR for recurrent or progressive disease
Approval duration
1 year